DRG Market Assessment reports

Squamous cell carcinoma of the head and neck (SCCHN) is the seventh most commonly diagnosed cancer. It encompasses a spectrum of heterogeneous tumors originating at multiple sites in the head and…

Acute coronary syndrome (ACS) is an umbrella term encompassing myocardial infarction and unstable angina. This report focuses on the secondary prevention of ACS (post-ACS), aimed at preventing…

The psoriatic arthritis (PsA) treatment market is experiencing significant shifts with the introduction of newer targeted therapies, such as AbbVie’s Rinvoq and Skyrizi, and UCB’s bimekizumab…

Epilepsy is a complex neurological disorder marked by recurrent seizures, affecting approximately 4.7 million people across the major markets, as reported by Clarivate Epidemiology. Given epilepsy…

Hormonal therapy remains the foundation of drug treatment for prostate cancer across all patient populations, with ADT serving as the universal backbone. ARPIs—enzalutamide, apalutamide, and…

Diabetic nephropathy (DN), also referred to as diabetic kidney disease, is a common complication of diabetes. The DN drug market comprises a wide variety of antidiabetic and antihypertensive drugs…

The major depressive disorder (MDD) therapy market is crowded and highly genericized. The prominent use of generic drugs such as selective serotonin reuptake inhibitors (SSRIs) as early-line…

Myasthenia gravis (MG) is a rare autoimmune disorder in which antibodies impair acetylcholinemediated neuromuscular transmission, causing fluctuating muscle weakness. Generalized MG (gMG) often…

The mature Parkinson’s disease treatment market continues to evolve as newly launched pump therapies (i.e., AbbVie’s Vyalev, Supernus’s Onapgo), extended-release levodopa formulations (i.e.,…

Hormonal agents dominate the treatment landscape for prostate cancer and are routinely used in all lines of therapy. Second-generation hormone therapies have expanded beyond metastatic castrate-…

KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into physicians’ treatment sequences and understand whom to position…

The urticaria drug market is dominated by oral medications, including steroids and second-generation, nondrowsy antihistamines, which are prescribed for both chronic inducible urticaria (CIndU) and…